Skip to main content
. Author manuscript; available in PMC: 2025 Mar 1.
Published in final edited form as: Addiction. 2023 Nov 15;119(3):411–437. doi: 10.1111/add.16370

Table 2:

Quality Assessment of Included Studies Using the NOS

Author, Year Selection Comparability Outcome or Exposure Total Points+
1 2 3 4 1a* 1b 1** 2 3
Bada et al., 2005(48) 9
Baer et al., 2019(97) 9
Bandoli et al., 2021a(93) 8
Bandoli et al., 2021b(94) 8
Betts et al., 2022(64) 8
Brown et al., 2016(95) 8
Burns et al., 2006(96) 8
Chabarria et al., 2016(99) 7
Coleman-Cowger et al., 2018(40) 9
Conner et al., 2015(4, 28) 9
Corsi et al., 2019(4) 8
Crume et al., 2018(97) 8
Day et al.,1994 9
Dotters-Katz et al., 2017(50) 7
Eiden et al., 2018(114) 9
El Marroun et al., 2011(61) 7
El Marroun et al., 2016(63) 7
Fried et al., 1988(55) 7
Fried et al., 1990(51) 7
Fried et al., 1992(60) 7
Gabrhelik et al., 2020(98) 8
Goldschmidt et al., 2007(65) 8
Gray et al., 2010(41) 9
Greiner et al., 2020(99) 9
Grewen et al.,2015(57) 9
Haight et al., 2021(100) 8
Hayatbakhsh et al., 2012(101) 8
Howard et al., 2019(42) 9
Kharbanda et al., 2020(102) 9
Koto et al., 2022(103) 8
Lee et al., 2020(43) 9
Leech et al., 1999(66) 9
Mark et al., 2016(104) 9
Michalski et al., 2020(103) 8
Moore et al., 2023(70) 9
Murnern et al. 2021(67) 9
Nawa et al.,(104) 8
Nguyen et al., 2022(105) 8
Noland et al., 2003(68) 9
Noland et al., 2005(26) 9
O’Connell & Fried, 1991(51) 8
Ostrea et al., 1997(106) 7
Prunet et al., 2017(46) 6
Richardson et al., 1995(54) 9
Roca et al., 2020(107) 7
Rodriquez et al., 2019(108) 8
Rompala et al., 2021(71) 8
Sasso et al., 2021(109) 7
Saurel-Cubizolles et al., 2014(110) 6
Scuhetze et al., 2019(115) 8
Shi et al., 2020(47) 8
Shiono et al., 1995(111) 8
Smid et al., 2021(52) 9
Straub et al., 2021(112) 9
Stroud et al., 2018(53) 9
Van Gelder et al., 2010(113) 9
Warshak et al., 2015(27) 9
+

Newcastle Ottawa Scale (NOS) Scores of 7–9 indicate high methodological quality, 5–6 indicate medium methodological quality, and 1–4 indicate low methodological quality

*,

study controls for other substance use

**,

follow-up time of >30 days (for prospective studies only)